Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 4c26326a57a4cc1dd18bec9e41e738cae71bfe3f
First added on: Feb 11, 2025